HomeCompareBSX vs GPN

BSX vs GPN: Dividend Comparison 2026

BSX yields 3.18% · GPN yields 1.51%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GPN wins by $10.3K in total portfolio value
10 years
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →
GPN
GPN
● Live price
1.51%
Share price
$66.30
Annual div
$1.00
5Y div CAGR
27.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$2,458.46
Full GPN calculator →

Portfolio growth — BSX vs GPN

📍 GPN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSXGPN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSX + GPN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSX pays
GPN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
GPN
Annual income on $10K today (after 15% tax)
$128.21/yr
After 10yr DRIP, annual income (after tax)
$2,089.69/yr
At 15% tax rate, GPN beats the other by $2,089.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSX + GPN for your $10,000?

BSX: 50%GPN: 50%
100% GPN50/50100% BSX
Portfolio after 10yr
$25.4K
Annual income
$1,229.39/yr
Blended yield
4.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
GPN
Analyst Ratings
37
Buy
21
Hold
4
Sell
Consensus: Buy
Price Target
$94.25
+42.2% upside vs current
Range: $80.00 — $109.00
Altman Z
0.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSX buys
6
GPN buys
0
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSXGPN
Forward yield3.18%1.51%
Annual dividend / share$2.00$1.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%27.6%
Portfolio after 10y$20.2K$30.5K
Annual income after 10y$0.32$2,458.46
Total dividends collected$321.00$9.1K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$108.35$94.25

Year-by-year: BSX vs GPN ($10,000, DRIP)

YearBSX PortfolioBSX Income/yrGPN PortfolioGPN Income/yrGap
1← crossover$10,859$158.91$10,892$192.46$33.00GPN
2$11,700$80.63$11,905$249.99$205.00GPN
3$12,559$40.60$13,064$325.83$505.00GPN
4$13,459$20.36$14,405$426.40$946.00GPN
5$14,411$10.20$15,974$560.68$1.6KGPN
6$15,425$5.10$17,834$741.46$2.4KGPN
7$16,507$2.55$20,069$987.14$3.6KGPN
8$17,664$1.28$22,799$1,324.75$5.1KGPN
9$18,901$0.64$26,189$1,794.67$7.3KGPN
10$20,225$0.32$30,481$2,458.46$10.3KGPN

BSX vs GPN: Complete Analysis 2026

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →

GPNStock

Global Payments Inc. provides payment technology and software solutions for card, electronic, check, and digital-based payments in the Americas, Europe, and the Asia-Pacific. It operates through three segments: Merchant Solutions, Issuer Solutions, and Business and Consumer Solutions. The Merchant Solutions segment offers authorization services, settlement and funding services, customer support and help-desk functions, chargeback resolution, terminal rental, sales and deployment, payment security services, consolidated billing and statements, and on-line reporting services. This segment also provides an array of enterprise software solutions that streamline business operations of its customers in various vertical markets; and value-added services, such as point-of-sale solutions, and analytic and engagement tools, as well as payroll and human capital management services. The Issuer Solutions segment offers solutions that enable financial institutions and retailers to manage their card portfolios through a platform; and commercial payments and ePayables solutions for businesses and governments. The Business and Consumer Solutions segment provides general-purpose reloadable prepaid debit and payroll cards, demand deposit accounts, and other financial service solutions to the underbanked and other consumers, and businesses under the Netspend brand. It markets its products and services through direct sales force, trade associations, agent and enterprise software providers, referral arrangements with value-added resellers, and independent sales organizations. The company was founded in 1967 and is headquartered in Atlanta, Georgia.

Full GPN Calculator →
📬

Get this BSX vs GPN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSX vs SCHDBSX vs JEPIBSX vs OBSX vs KOBSX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.